## **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# SCHEDULE 13G (Rule 13d-102)

## INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 1)<sup>1</sup>

Allakos Inc.
(Name of Issuer)
Common Stock, par value \$0.001 per share
(Title of Class of Securities)
01671P100
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, <i>see</i> the <i>Notes</i> ).

1	NAME OF REPOR	RTING PERSON	
	Biotechnolog	gy Value Fund, L.P.	
2		PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER  0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 4,558,983	
PERSON WITH	7	SOLE DISPOSITIVE POWER  0	
	8	SHARED DISPOSITIVE POWER 4,558,983	
9	AGGREGATE AM 4,558,983	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10		THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPOR	TING PERSON	
	PN		

	ALCE OF BEDODE	DIC DEDCOM	
I N	AME OF REPORT	ING PERSON	
	BVF I GP LLC		
2 CI	HECK THE APPRO	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3 SE	EC USE ONLY		
4 CI	ITIZENSHIP OR P	LACE OF ORGANIZATION	-
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		4,558,983	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		4,558,983	
9 A(	GGREGATE AMO	UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	4,558,983		
10 CI	HECK BOX IF TH	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11 PE	ERCENT OF CLAS	SS REPRESENTED BY AMOUNT IN ROW (9)	
	5.2%		
12 TY	YPE OF REPORTI	NG PERSON	
	OO		

1	NAME OF REPOR	RTING PERSON	
	Biotechnolog	gy Value Fund II, L.P.	
2		PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	_
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 3,469,576	
PERSON WITH	7	SOLE DISPOSITIVE POWER  0	
	8	SHARED DISPOSITIVE POWER 3,469,576	
9	AGGREGATE AM	10UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	3,469,576		
10		THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	4.0%		
12	TYPE OF REPOR	TING PERSON	
	PN		

	NAME OF BEROR	EDIO DEDOON	
1	NAME OF REPOR	TING PERSON	
	DAE II CD I		
	BVF II GP L		
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
	and tian out to		
3	SEC USE ONLY		
4	CITIZENCIUD OD	PLACE OF ORGANIZATION	
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES		SOLL VOTINGTOWER	
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		3,469,576	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0	
	8	SHARED DISPOSITIVE POWER	
		2.162.776	
	A CODECATE AM	3,469,576	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	3,469,576		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П
10	CHECK BOX II' I	TIL MOOKLOME MITOUT IN KOW (7) EACLODES CERTAIN SHAKES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
		2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
	4.0%		
12	TYPE OF REPORT	TING PERSON	
	00		

1	NAME OF REPO	RTING PERSON	
	Biotechnolo	gy Value Trading Fund OS LP	
2		PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OF	R PLACE OF ORGANIZATION	
	Cayman Isla	unds	
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER  0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER 406,794	
PERSON WITH	7	SOLE DISPOSITIVE POWER  0	
	8	SHARED DISPOSITIVE POWER	
9	AGGREGATE AN	406,794 MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	406,794		
10		THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	Less than 19		
12	TYPE OF REPOR	TING PERSON	
	PN		

1	NAME OF REPO	RTING PERSON	
	BVF Partner		
2	CHECK THE API	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OF	R PLACE OF ORGANIZATION	
	Cayman Isla	nds	
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		406,794	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	,		
		0	
	8	SHARED DISPOSITIVE POWER	
		406,794	
9	AGGREGATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	406,794		
10		THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
			_
11	PERCENT OF CI	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	Less than 19	6	
12	TYPE OF REPOR		
12		in to 1 Blood.	
	CO		

1	NAME OF REPOR	TING PERSON	
	BVF GP Hol	dings LLC	
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER  0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER  8,028,559	
PERSON WITH	7	SOLE DISPOSITIVE POWER  0	
	8	SHARED DISPOSITIVE POWER  8,028,559	
9	AGGREGATE AM 8,028,559	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORT	TING PERSON	

1	NAME OF REPOR	TING PERSON	
	BVF Partners	s.L.P.	
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER  0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER  8,552,417	
PERSON WITH	7	SOLE DISPOSITIVE POWER  0	
	8	SHARED DISPOSITIVE POWER  8,552,417	
9	AGGREGATE AM 8,552,417	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	TYPE OF REPORT	TING PERSON	

1	NAME OF REPOR	RTING PERSON	
	BVF Inc.		
2		ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0	
OWNED BY EACH REPORTING	6	SHARED VOTING POWER  8,552,417	
PERSON WITH	7	SOLE DISPOSITIVE POWER  0	
	8	SHARED DISPOSITIVE POWER  8,552,417	
9	AGGREGATE AM	IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	8,552,417		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11		ASS REPRESENTED BY AMOUNT IN ROW (9)	
12	9.8% TYPE OF REPOR	FING DED CON	
12		TING FERSON	
	СО		

1	NAME OF REPORT	TING PERSON	
1	While of Reform	TINGTEROON	
	Mark N. Lam	pert	
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR 1	PLACE OF ORGANIZATION	
	United States		
NUMBER OF	5	SOLE VOTING POWER	
SHARES BENEFICIALLY		0	
OWNED BY	6	SHARED VOTING POWER	
EACH	Ů	SIMILED VOTINGTOWER	
REPORTING		8,552,417	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
	8	0 SHARED DISPOSITIVE POWER	
	8	SHARED DISTOSITIVE TO WER	
		8,552,417	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	0.550.445		
10	8,552,417	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
10	CHECK BOX IF 11	ie Addredate Amount in Row (9) Excludes Certain Shares	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	0.007		
12	9.8%	INC DEDGON	
12	TYPE OF REPORT	ING PERSUN	
	IN		

#### Item 1(a). Name of Issuer:

Allakos Inc., a Delaware corporation (the "Issuer").

#### Item 1(b). Address of Issuer's Principal Executive Offices:

825 Industrial Road, Suite 500 San Carlos, California 94070

## Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

#### Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF II GP LLC ("BVF2 GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

## Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.001 per share (the "Shares").

### Item 2(e). CUSIP Number:

01671P100

## Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
(j)	//	A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:

#### Item 4. Ownership

#### (a) Amount beneficially owned:

As of the close of business on December 31, 2023, (i) BVF beneficially owned 4,558,983 Shares, (ii) BVF2 beneficially owned 3,469,576 Shares and (iii) Trading Fund OS beneficially owned 406,794 Shares.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 4,558,983 Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 3,469,576 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 406,794 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 8,028,559 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 8,552,417 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in a certain Partners managed account (the "Partners Managed Account"), including 117,064 Shares held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 8,552,417 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 8,552,417 Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

#### (b) Percent of class:

The following percentages are based on 87,476,338 Shares outstanding as of November 7, 2023, which is the total number of Shares outstanding as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2023.

As of the close of business on December 31, 2023, (i) BVF beneficially owned approximately 5.2% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 4.0% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 5.2% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 4.0% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.2% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.8% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

#### Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

#### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to the Schedule 13G filed with the Securities and Exchange Commission on September 29, 2022.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURE**

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: January 18, 2024

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC, its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC, its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert

President

/s/ Mark N. Lampert

MARK N. LAMPERT

17